TRAWHIGH SIGNALFINANCIAL10-K

TRAW's operating losses were substantially reduced while the company significantly decreased its asset base and liabilities, suggesting major restructuring or asset disposition activity.

The dramatic improvement in operating performance alongside substantial reductions in both assets and liabilities indicates either a major business restructuring, asset sale, or significant cost-cutting initiative. The company's cash position declined moderately while operating cash flows improved, suggesting better operational efficiency despite the smaller asset base.

Comparing 2026-04-15 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

TRAW's financial profile changed dramatically, with operating losses substantially reduced from the prior period while total assets declined by over half and liabilities dropped by 80%. The company's cash position decreased moderately to $20.6M, but operating cash flows improved meaningfully, indicating enhanced operational efficiency despite the significantly smaller balance sheet footprint.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+87.4%
-$142.4M-$17.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Total Liabilities
Balance Sheet
-80.1%
$56.6M$11.2M

Liabilities reduced 80.1% — deleveraging improves balance sheet strength and financial flexibility.

Current Assets
Balance Sheet
-68%
$25.0M$8.0M

Current assets declined 68% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-57.5%
$25.0M$10.6M

Total assets contracted 57.5% — asset sales, write-downs, or balance sheet optimization underway.

Interest Expense
P&L
-50%
$4K$2K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
-46.6%
$38.5M$20.6M

Cash declined 46.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
+39%
-$29.8M-$18.2M

Operating cash flow surged 39% — exceptional cash generation, highest quality earnings signal.

LANGUAGE CHANGES
NEW — 2026-04-15
PRIOR — 2025-03-31
ADDED
The evaluated dose levels included 80, 120, 240, and 480 mg administered orally in capsule form.
The primary endpoints of the study were safety and tolerability; the secondary and other endpoints included determination of a drug pharmacokinetic profile.
The study enrolled healthy volunteers, adults 18-64 years old, into 4 cohorts.
Topline data showed good overall tolerability and a pharmacokinetic profile.
Sixteen AEs were recorded, of which three were possibly related to study drug during the study; all were mild headaches and resolved without treatment.
+7 more — sign up free →
REMOVED
The dose levels that were evaluated included 80, 120, 240, and 480 mg, taken once via oral capsules.
The primary endpoint of the study was the measurement of safety and tolerability, and the secondary and other endpoints included the determination of the drug pharmacokinetic profile.
Topline data showed good overall tolerability and a pharmacokinetic profile that appears to support the potential use of tivoxavir marboxil as a one-time treatment for influenza.
Sixteen AEs were recorded, of which three were reported as possibly related to study drug during the study; all were mild headaches.
Topline data from this study showed that a single dose of tivoxavir marboxil maintained plasma drug levels consistently above the EC90 and within the predicted therapeutic window for more than 23 days.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →